chrX-123184537-T-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 8P and 5B. PVS1BS1_SupportingBS2
The NM_000828.5(GRIA3):āc.2T>Cā(p.Met1?) variant causes a start lost change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000147 in 1,090,266 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 6 hemizygotes in GnomAD. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: not found (cov: 20)
Exomes š: 0.000015 ( 0 hom. 6 hem. )
Consequence
GRIA3
NM_000828.5 start_lost
NM_000828.5 start_lost
Scores
3
2
8
Clinical Significance
Conservation
PhyloP100: 0.295
Genes affected
GRIA3 (HGNC:4573): (glutamate ionotropic receptor AMPA type subunit 3) Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes composed of multiple subunits, arranged to form ligand-gated ion channels. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. The subunit encoded by this gene belongs to a family of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive glutamate receptors, and is subject to RNA editing (AGA->GGA; R->G). Alternative splicing at this locus results in different isoforms, which may vary in their signal transduction properties. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PVS1
Start lost variant, no new inframe start found.
BS1
Variant frequency is greater than expected in population mid. gnomad4_exome allele frequency = 0.0000147 (16/1090266) while in subpopulation MID AF= 0.000486 (2/4115). AF 95% confidence interval is 0.0000855. There are 0 homozygotes in gnomad4_exome. There are 6 alleles in male gnomad4_exome subpopulation. Median coverage is 29. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Hemizygotes in GnomAdExome4 at 6 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GRIA3 | NM_000828.5 | c.2T>C | p.Met1? | start_lost | 1/16 | ENST00000622768.5 | NP_000819.4 | |
GRIA3 | NM_007325.5 | c.2T>C | p.Met1? | start_lost | 1/16 | ENST00000620443.2 | NP_015564.5 | |
GRIA3 | NM_001256743.2 | c.2T>C | p.Met1? | start_lost | 1/4 | NP_001243672.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GRIA3 | ENST00000620443.2 | c.2T>C | p.Met1? | start_lost | 1/16 | 1 | NM_007325.5 | ENSP00000478489 | P4 | |
GRIA3 | ENST00000622768.5 | c.2T>C | p.Met1? | start_lost | 1/16 | 5 | NM_000828.5 | ENSP00000481554 | A1 |
Frequencies
GnomAD3 genomes Cov.: 20
GnomAD3 genomes
Cov.:
20
GnomAD3 exomes AF: 0.0000273 AC: 5AN: 183430Hom.: 0 AF XY: 0.0000295 AC XY: 2AN XY: 67906
GnomAD3 exomes
AF:
AC:
5
AN:
183430
Hom.:
AF XY:
AC XY:
2
AN XY:
67906
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000147 AC: 16AN: 1090266Hom.: 0 Cov.: 29 AF XY: 0.0000168 AC XY: 6AN XY: 356216
GnomAD4 exome
AF:
AC:
16
AN:
1090266
Hom.:
Cov.:
29
AF XY:
AC XY:
6
AN XY:
356216
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 20
GnomAD4 genome
Cov.:
20
Alfa
AF:
Hom.:
ExAC
AF:
AC:
6
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:4
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change affects the initiator methionine of the GRIA3 mRNA. The next in-frame methionine is located at codon 7. This variant is present in population databases (rs752728469, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with GRIA3-related conditions. ClinVar contains an entry for this variant (Variation ID: 624438). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 22, 2022 | Initiation codon variant in a gene for which loss-of-function is not a known mechanism of disease; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 34426522, 28152038) - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 07, 2014 | The p.M1? pathogenic mutation (also known as c.2T>C), located in coding exon 1 of the GRIA3 gene, results from a T to C substitution at nucleotide position 2. This alters the methionine residue at the native initiation codon. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples with coverage at this position. Sequence variations that modify the initiation codon (ATG) are expected to cause a shift in the mRNA reading frame and possibly absence of protein translation. However, this amino acid position is not well conserved and a number of species do not have the initiation codon at this position. Furthermore, another ATG that is highly conserved among species is located down stream. The ATG sequence, located six amino acids down stream from the human reference sequence, is purported to function as the start site for rat GluR3 based on cDNA studies (Rampersad, V et al. Biochim Biophys Acta 1994;1219:563-6). In humans, iontropic flutamate receptors (iGluR) are purported to contain a short signal peptide (between 14-33 amino acids long) at the N-terminus that targets the protein to the cell membrane and mislocalization may disuprt neuronal function (Traynelis SF, Pharmacol. Rev. 2010 Sep; 62(3):405-96). It is anticipated that the p.M1? alteration, would result in the shortening of the signal peptide and lead to mislocalization of the hGluR3 protein; however direct evidence on this alteration's affect on transport to the cell membrane is unavailable. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;T;T;T;T;.
FATHMM_MKL
Benign
N
LIST_S2
Uncertain
.;D;D;D;.;D
M_CAP
Benign
D
MetaRNN
Uncertain
D;D;D;D;D;D
MetaSVM
Benign
T
MutationTaster
Benign
N;N;N;N;N;N
PROVEAN
Benign
.;.;.;.;N;.
Sift
Pathogenic
.;.;.;.;D;.
Sift4G
Pathogenic
D;.;D;D;.;D
Polyphen
0.0
.;B;.;.;B;B
Vest4
MutPred
Gain of phosphorylation at M1 (P = 0.0331);Gain of phosphorylation at M1 (P = 0.0331);Gain of phosphorylation at M1 (P = 0.0331);Gain of phosphorylation at M1 (P = 0.0331);Gain of phosphorylation at M1 (P = 0.0331);Gain of phosphorylation at M1 (P = 0.0331);
MVP
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at